NCT02221362
Late-onset Pompe Patients Untreated or Treated With rhGAA
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
Study 701-901, a multicenter, multinational, longitudinal, non-interventional observational study in subjects, at least 18 years old, diagnosed with late-onset Pompe disease prospectively collects data to understand clinical progression in terms of respiratory function, symptomology, genotype, biochemistry, endurance and selected subject-reported measures for 24 weeks followed by a 240 week additional observation period for up to 100 subjects.
All
From 18 Years
No
Observational
30
2014-12
2016-10-31
Westmead, New South Wales, Australia
Adelaide, South Australia, Australia
Clayton, Victoria, Australia
Porto Alegre, , Brazil
Recife, , Brazil
Ribeirao Preto, , Brazil
Calgary, Alberta, Canada
Alexandroupolis, , Greece
Athens, , Greece
Larissa, , Greece
Thessalonika, , Greece
Dublin, , Ireland
Seoul, , Korea, Republic of
Gdansk, , Poland
Krakow, , Poland
Warsaw, , Poland
Constanta, , Romania
Belgrade, , Serbia
Singapore, , Singapore
Ljubljana, , Slovenia
Barcelona, , Spain
Madrid, , Spain
Valencia, , Spain
Taipei, , Taiwan
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields